Lineage Q3 net loss widens to $29.8M on warrant remeasurement; cash $40.5M

Lineage Cell Therapeutics, Inc.

2025-Q3 EPS reported -$0.28 vs consensus -$0.03 ▼ miss (-968.7%)

Net loss $29.8M ($0.13/sh) vs $3.0M ($0.02) in Q3 2024; includes $26.6M non-cash warrant remeasurement.
Revenue $3.7M, down ~$0.1M YoY; cash $40.5M expected to fund ops into Q2 2027.
Entered collaboration with William Demant Invest for ReSonance (ANP1); up to $12M development funding.
Positive 36-month OpRegen (RG6501) data in dry AMD presented at CTS 2025.
First chronic SCI participant dosed in OPC1 DOSED study; no safety events at 60 days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.